Tracon terminates ENVASARC trial, will explore strategic alternatives
PremiumThe FlyTracon terminates ENVASARC trial, will explore strategic alternatives
3M ago
TRACON Pharmaceuticals Announces Termination of ENVASARC Trial and Will Explore Strategic Alternatives Leveraging its In-House Product Development Platform
Premium
Press Releases
TRACON Pharmaceuticals Announces Termination of ENVASARC Trial and Will Explore Strategic Alternatives Leveraging its In-House Product Development Platform
3M ago
TRACON Pharmaceuticals Announces Executive Officer Resignation
Premium
Company Announcements
TRACON Pharmaceuticals Announces Executive Officer Resignation
3M ago
TRACON Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update
PremiumPress ReleasesTRACON Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update
4M ago
David Lazar Joins TRACON Pharmaceuticals as Chief Business Officer
Premium
Company Announcements
David Lazar Joins TRACON Pharmaceuticals as Chief Business Officer
4M ago
TCON Earnings Report this Week: Is It a Buy, Ahead of Earnings?
Premium
Pre-Earnings
TCON Earnings Report this Week: Is It a Buy, Ahead of Earnings?
4M ago
Tracon Pharmaceuticals announces 1-for-20 reverse stock split
PremiumThe FlyTracon Pharmaceuticals announces 1-for-20 reverse stock split
5M ago
Tracon Pharmaceuticals price target lowered to $3 from $6 at H.C. Wainwright
Premium
The Fly
Tracon Pharmaceuticals price target lowered to $3 from $6 at H.C. Wainwright
6M ago
Tracon says IDMC reccommends ENVASARC Phase 2  trial continue ‘as planned’
Premium
The Fly
Tracon says IDMC reccommends ENVASARC Phase 2 trial continue ‘as planned’
6M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100